Anemia is a common cause of qualitative or quantitative deficiency of hemoglobin. Hemoglobin is an iron-rich protein that carries oxygen from the lungs to other parts of the body. Hemoglobin deficiency is commonly associated with low red blood cell count and hematocrit. Anemia reduces the movement of oxygen to the rest of the body. Anemia can be easily prevented and treated, but detection of anemia has mild or vague symptoms, making anemia almost undetectable. In general, patients with anemia show symptoms such as weakness, malaise, malaise, and poor concentration due to exercise.
In addition, as the anemia progresses, patients suffer from exercise-induced shortness of breath, and cardiac output increases, causing palpitations, nausea, and heart failure. Anemia is commonly seen in patients with nutritional deficiencies (anemia or vitamin diets), chronic diseases (such as cancer, kidney disease, diabetes), chronic infections (such as HIV, tuberculosis), and high blood loss (such as blood loss). increase. due to injury, menstrual bleeding, surgery, etc.).
Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/21364
Anemia is an inherited or acquired disorder that affects hemoglobin synthesis, such as sickle cell anemia and thalassemia. Additionally, depletion of bone marrow and stem cells can lead to anemia. More than 400 types of anemia have been diagnosed, each with different causes and symptoms.
High prevalence of undernourishment is a major driver of the global anemia drugs market. WHO estimates that approximately 50% of anemia cases are reported to be due to iron deficiency. Increasing prevalence of chronic diseases and chronic diseases and increasing flowering population of babies are expanding the anemia drugs market.
Increasing anemia due to lack of proper nutritional diet in developing countries is expanding the anemia drug market. According to the World Bank, anemia is the eighth most common cause of illness among women and girls. Government initiatives to improve healthcare facilities in developing countries are estimated to drive market growth.
However, side effects associated with anemia drug medication are expected to hamper the market growth. For example, diabetics taking iron for anemia may have an increased risk of heart disease. Continued research and development related to anemia drugs and growing awareness of anemia in developing and underdeveloped countries are expected to create new opportunities for the market during the forecast period.
Request Table of Contents @ https://www.persistencemarketresearch.com/toc/21364
The global anemia drugs market is segmented on the basis of anemia type, drug, distribution channel, and geography.
| anemia type |
|
| drugs |
|
| Distribution channel |
|
Access Full Report @ https://www.persistencemarketresearch.com/checkout/21364
Rising intake of NSAIDs due to busy lifestyles such as aspirin and ibuprofen leading to ulcers causing anemia and gastritis is significantly increasing market growth globally. Increasing awareness of anemia treatment drugs in developing countries is expected to drive the market growth.
Moreover, increasing research and development related to anemia drugs is expected to drive the growth of the anemia drugs market during the forecast period. For example, in November 2017, the FDA approved Auryxia® (ferric citrate) tablets instead of dialysis for the treatment of patients with iron deficiency anemia and chronic kidney disease.
North America occupies a large share of the anemia drug market, as chronic diseases such as lifestyle-related diseases, diabetes, and cancer are on the rise. Additionally, the Asia Pacific and Middle East and Africa regions are expected to exhibit substantial growth rates owing to increased government investment in the healthcare sector and growing awareness of anemia in the region.
Major companies present in the global anemia drug market include Amgen Inc., Keryx Biopharmaceuticals, Inc., GlaxoSmithKline plc, Pfizer Inc., Emmaus Medical Inc., Allergan Inc., Meda Cuonsumer Healthcare Inc., F.S. We have Hoffmann LaRoche AG. , Abbvie Inc, Johnson and Johnson, and others. Both companies are focusing on research and development of new drugs to increase their market share in the anemia treatment market.
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
Website – www.persistencemarketresearch.com